Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EDWARD A MENA

Allopathic & Osteopathic Physicians Internal Medicine Hepatology

NPI
1881654226
CMS profile
85033
Location
PASADENA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$88,172.13

274 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 6; records 151–200 of 274 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EDWARD A MENA

NPI 1881654226 · CMS profile ID 85033

Allopathic & Osteopathic Physicians / Internal Medicine / Hepatology

PASADENA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 274 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881654226?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EDWARD A MENA, NPI 1881654226, CMS profile ID 85033. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 274 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881654226?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). EDWARD A MENA, NPI 1881654226, CMS profile ID 85033. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 274 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881654226?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
EDWARD A MENA, NPI 1881654226, CMS profile ID 85033, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 274 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1881654226?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

274 matching records · $88,172.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 274 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 274.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $19.0806/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681564091 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $10.9206/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684834409 CMS
EISAI INC. $22.4006/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697007167 CMS
Merck Sharp & Dohme Corporation $6.5406/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695726637 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $3.3406/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684834407 CMS
Shionogi Inc $9.9505/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688781293 CMS
Intercept Pharmaceuticals, Inc. $11.3605/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702092497 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.4205/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684834401 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.2705/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684834405 CMS
Gilead Sciences, Inc. $7.6605/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681564089 CMS
AbbVie, Inc. $2,250.0005/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648239753 CMS
Dova Pharmaceuticals $2,625.0005/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705227353 CMS
Dova Pharmaceuticals $109.3305/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705229907 CMS
AbbVie, Inc. $34.0505/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648239757 CMS
Intercept Pharmaceuticals, Inc. $12.0305/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702092491 CMS
Merck Sharp & Dohme Corporation $18.7505/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695587547 CMS
AbbVie, Inc. $124.9905/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648239755 CMS
Dova Pharmaceuticals $21.8905/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705232093 CMS
E.R. Squibb & Sons, L.L.C. $12.2505/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651247377 CMS
Shionogi Inc $7.2205/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688781275 CMS
AbbVie, Inc. $23.1605/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648239761 CMS
Merck Sharp & Dohme Corporation $15.8805/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695584711 CMS
EISAI INC. $8.0205/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697041367 CMS
Intercept Pharmaceuticals, Inc. $20.9805/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702092485 CMS
Gilead Sciences, Inc. $3,720.0005/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679313653 CMS
Gilead Sciences, Inc. $27.4605/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681564079 CMS
Gilead Sciences, Inc. $36.9905/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681564081 CMS
Gilead Sciences, Inc. $47.0305/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681564083 CMS
Gilead Sciences, Inc. $49.2205/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681564085 CMS
Gilead Sciences, Inc. $49.9505/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681564087 CMS
Gilead Sciences, Inc. $150.0005/03/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679261437 CMS
AbbVie, Inc. $20.8304/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648239751 CMS
AbbVie, Inc. $1.9604/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648239759 CMS
Dova Pharmaceuticals $22.7504/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705231735 CMS
E.R. Squibb & Sons, L.L.C. $2.9004/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651247375 CMS
Intercept Pharmaceuticals, Inc. $121.5604/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702092477 CMS
Intercept Pharmaceuticals, Inc. $2,600.0004/25/2019 Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702092481 CMS
Merck Sharp & Dohme Corporation $17.8704/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695455283 CMS
E.R. Squibb & Sons, L.L.C. $14.7504/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651247373 CMS
Shionogi Inc $21.2104/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688781299 CMS
Intercept Pharmaceuticals, Inc. $500.0004/17/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702092473 CMS
EISAI INC. $22.7104/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697003937 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.9404/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684834399 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $4.9104/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684834393 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $11.1004/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684834395 CMS
Gilead Sciences, Inc. $1,150.0004/13/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679261435 CMS
Gilead Sciences, Inc. $83.5304/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681564077 CMS
Dova Pharmaceuticals $158.0404/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705228311 CMS
Gilead Sciences, Inc. $23.8704/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681564073 CMS
Gilead Sciences, Inc. $41.4704/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681564075 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $88,172.13 274
PY2020 $48,915.49 224
PY2021 $67,358.17 216
PY2022 $74,212.53 168
PY2023 $68,722.98 117
PY2024 $130,158.91 232
PY2025 $146,457.55 253

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,311.04 2
PY2025 Principal investigator $851,362.05 73
PY2024 Recipient $32,488.21 2
PY2024 Principal investigator $625,989.95 106
PY2023 Principal investigator $705,324.05 50
PY2022 Principal investigator $461,189.55 32
PY2021 Recipient $2,869.95 1
PY2021 Principal investigator $324,222.56 44
PY2020 Principal investigator $551,824.76 59
PY2019 Principal investigator $795,403.40 69

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

75 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Madrigal Pharmaceuticals $7,917.75 12/19/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254347
Recipient Eli Lilly and Company $1,395.66 12/17/2025 Covered Recipient Physician A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187870971
Recipient Eli Lilly and Company $915.38 12/17/2025 Covered Recipient Physician A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187872095
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 12/17/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208574
Principal investigator 1 Gilead Sciences, Inc. $4,700.00 12/17/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208581
Principal investigator 1 Gilead Sciences, Inc. $7,500.00 12/17/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208588
Principal investigator 1 Gilead Sciences, Inc. $57.80 12/17/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208602
Principal investigator 1 Madrigal Pharmaceuticals $38,116.59 12/11/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,621.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274572
Principal investigator 1 Genentech, Inc. $6,265.00 12/10/2025 Non-covered Recipient Entity
CALIFORNIA LIVER INSTITUTE
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211582565
Principal investigator 1 Madrigal Pharmaceuticals $2,639.25 12/10/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253690
Principal investigator 1 Madrigal Pharmaceuticals $2,234.25 12/10/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253694
Principal investigator 1 Madrigal Pharmaceuticals $2,234.25 12/10/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253718
Principal investigator 1 Madrigal Pharmaceuticals $4,873.50 12/10/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253750
Principal investigator 1 Madrigal Pharmaceuticals $7,512.75 12/10/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253754
Principal investigator 1 Madrigal Pharmaceuticals $6,702.75 12/10/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253758
Principal investigator 1 Madrigal Pharmaceuticals $2,234.25 12/10/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253762
Principal investigator 1 Madrigal Pharmaceuticals $10,462.50 12/10/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253766
Principal investigator 1 Madrigal Pharmaceuticals $3,165.75 12/10/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253770
Principal investigator 1 Madrigal Pharmaceuticals $6,412.50 12/10/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253774
Principal investigator 1 Madrigal Pharmaceuticals $38,469.62 12/10/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,474.02 12/10/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184270181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,300.64 12/04/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184269151
Principal investigator 1 Gilead Sciences, Inc. $15,284.00 11/14/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,950.96 11/14/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184261307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,857.06 11/07/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184258927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,621.10 10/16/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,815.72 10/03/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184244625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,769.40 09/18/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184240446
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 09/17/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203973
Principal investigator 1 Gilead Sciences, Inc. $5,500.00 09/17/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203978
Principal investigator 1 Gilead Sciences, Inc. $2,700.00 09/17/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203986
Principal investigator 1 Gilead Sciences, Inc. $1,500.00 09/17/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) No dispute reported 06/30/2026 1229203995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,417.00 09/12/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236538
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,995.46 08/26/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184230651
Principal investigator 1 Madrigal Pharmaceuticals $2,234.25 08/21/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248858
Principal investigator 1 Madrigal Pharmaceuticals $2,639.25 08/21/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248896
Principal investigator 1 Madrigal Pharmaceuticals $4,873.50 08/21/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248913
Principal investigator 1 Eli Lilly and Company $35,013.00 08/12/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187877949
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,847.90 08/04/2025 Non-covered Recipient Entity
California Liver Research Institute
Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis No dispute reported 06/30/2026 1220806437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $43,884.00 07/31/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184222812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,474.02 07/22/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217715
Principal investigator 1 Bausch Health US, LLC $2,592.43 07/09/2025 Non-covered Recipient Entity
California Liver Research Inst
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224836225
Principal investigator 1 Madrigal Pharmaceuticals $10,152.00 07/04/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246469
Principal investigator 1 Genentech, Inc. $20,000.00 07/01/2025 Non-covered Recipient Entity
CALIFORNIA LIVER INSTITUTE
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211582548
Principal investigator 1 Genentech, Inc. $2,855.00 07/01/2025 Non-covered Recipient Entity
CALIFORNIA LIVER INSTITUTE
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211582552
Principal investigator 1 Genentech, Inc. $2,500.00 07/01/2025 Non-covered Recipient Entity
CALIFORNIA LIVER INSTITUTE
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211582556
Principal investigator 1 Genentech, Inc. $3,000.00 07/01/2025 Non-covered Recipient Entity
CALIFORNIA LIVER INSTITUTE
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211582560
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,629.08 06/24/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184210632
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,510.72 06/12/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184206219
Principal investigator 1 Bausch Health US, LLC $4,250.74 06/05/2025 Non-covered Recipient Entity
California Liver Research Inst
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224836254
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,124.82 06/05/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184204151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,190.26 05/28/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184198863
Principal investigator 1 Gilead Sciences, Inc. $37,115.00 05/21/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis No dispute reported 06/30/2026 1229208566
Principal investigator 1 Madrigal Pharmaceuticals $9,936.00 05/15/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243866
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,369.02 05/15/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184194617
Principal investigator 1 Bausch Health US, LLC $5,546.73 05/13/2025 Non-covered Recipient Entity
California Liver Research Inst
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224836258
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,930.20 05/08/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184193741
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,487.95 04/30/2025 Non-covered Recipient Entity
LONG ISLAND REGIONAL ARTHRITIS AND OSTEOPOROSIS CARE, PC
A Two Part Phase IIa b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants with Cirrhosis with Features of Portal Hypertension No dispute reported 06/30/2026 1185545721
Principal investigator 1 Madrigal Pharmaceuticals $34,215.09 04/23/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,973.50 04/15/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184183442
Principal investigator 1 Madrigal Pharmaceuticals $6,702.75 04/10/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242134
Principal investigator 1 Bausch Health US, LLC $5,322.21 04/01/2025 Non-covered Recipient Entity
California Liver Research Inst
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224836250
Principal investigator 1 AstraZeneca Pharmaceuticals LP $38,583.75 03/28/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Two Part Phase IIa b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants with Cirrhosis with Features of Portal Hypertension No dispute reported 06/30/2026 1185545719
Principal investigator 1 Bausch Health US, LLC $5,647.98 03/11/2025 Non-covered Recipient Entity
California Liver Research Inst
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224836246
Principal investigator 1 Madrigal Pharmaceuticals $12,985.65 03/06/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240274
Principal investigator 1 Bausch Health US, LLC $2,367.48 03/05/2025 Non-covered Recipient Entity
California Liver Research Inst
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224836231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,694.74 02/25/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184155394
Principal investigator 1 Madrigal Pharmaceuticals $10,260.00 02/06/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239104
Principal investigator 1 Bausch Health US, LLC $2,981.73 01/28/2025 Non-covered Recipient Entity
California Liver Research Inst
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224836236
Principal investigator 1 Madrigal Pharmaceuticals $102,111.36 01/23/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238736
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,973.50 01/17/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184148089
Principal investigator 1 Bausch Health US, LLC $9,797.47 01/13/2025 Non-covered Recipient Entity
California Liver Research Inst
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224836240
Principal investigator 1 Eli Lilly and Company $42,845.00 01/07/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187878245
Principal investigator 1 Madrigal Pharmaceuticals $20,439.00 01/03/2025 Non-covered Recipient Entity
CALIFORNIA LIVER RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238013